zolbetuximab
astellas
[]
40% of patients screened for spotlight trial were claudin positive = not a trivial number. great job and team! zolbetuximab is here to stay. #gi23
Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Passionate about clinical research, education and pt-prov communication. #gicancer #meded